Expert Insight: Automating tumor-specific 3D cultures for anti-cancer drug screening

March 24, 2020
Julia Kirshner, Ph.D.
Founder & CEO, zPREDICTA, Inc.

In this webinar we will discuss how 3D cell culture overcomes the limitations of traditional 2D culture when it comes to predicting the therapeutic potential of pharmaceutical compounds in development. We will describe how our Reconstructed Lung 3D culture platform (r-Lung) has successfully been adopted for testing of anti-cancer agents in high-throughput screening (HTS) format using the Tecan Freedom EVO® liquid handler and Tecan D300e Digital Dispenser, and how the platform provides a physiologically-relevant, automated 3D HTS system that can be incorporated throughout the drug development workflow for reliable identification of anti-cancer agents.

3D Cell Culture Technologies In Drug Development

January 31, 2019
Julia Kirshner, Ph.D.
Founder & CEO, zPREDICTA, Inc.

In this webinar we discuss zPREDICTA’s 3D disease models and their use in drug development emphasizing the capacity of our patient-derived platform to mimic the native architecture of human tissues in an organ- and disease-specific manner and its high correlation with clinical response.

Novel 3D Culture Technologies Utilizing Patient-Derived Tissue

July 12, 2016
Julia Kirshner, Ph.D. 
Founder & CEO, zPREDICTA, Inc.

In this webinar we summarize the current state of 3D culture technologies and highlight relevant applications of each platform.

Human cells have been grown in culture since the 1950s. However, conventional cell culture models lack tissue microenvironment, and thus, have limited physiological relevance. Emerging 3D culture systems are starting to incorporate various components of tissue microenvironment to better replicate the biology of human tissues.

0

Start typing and press Enter to search